PR Distribution Report [21092018331614284420815900]


v.3.517

REPORT DETAILS
PR Distribution Report ID: 21092018331614284420815900
PR Distribution Campaign ID: 331614284420815900
Customer: irena.turk@fotona.com
Email for Contacts: milan.grbovic@fotona.com
Press Release: New Study Reconfirms Effectiveness and Safety of Fotona Dynamis Laser Treatment for Minimally-Invasive Urinary Incontinence link opens in a new window
Press Release language: English
PR released on: Sep 21, 2018
Report started on: Sep 21, 2018
Report last updated on: Oct 5, 2018*

* Frequent updates on your PR distribution report are only done during the active period of your PR campaign. Further updates on this PR distribution report beyond the PR campaign period may be done on an irregular basis. You’ll be notified via an email if such an update has been made in future on your PR distribution report.
PR campaign duration:
The campaign duration depends on the PR distribution budget.
(Sep 21, 2018 – Oct 5, 2018 ~ 14 days)
Is PR campaign active?
The active period of your PR distribution campaign depends on the PR distribution budget.
No. The active period of your PR distribution campaign is over*.

Extend PR campaign & reach?

* Even if the active period of your PR distribution campaign is over, your press release remains alive and is up and running on EuropaWire and all the places it has been published on, released via, submitted to and appeared on. The active period of your PR distribution campaign depends on the PR distribution budget and can be anything between one week and 30+ days if larger PR distribution budgets are used. During the active period of your PR distribution campaign, EuropaWire uses its news-wire platform and market insights to proactively engage in leveraging some of today’s most sophisticated and precise multi-channel targeting options available online to source and reach out to the audience that might be interested in and engage with your PR message based on your targeting preferences. The larger the PR distribution budget the longer both the PR distribution campaign and the observed period covered by your PR distribution report.
PR report observed period:
The observed period for the PR distribution report depends on the PR distribution campaign duration.
(Sep 21, 2018 – Oct 5, 2018 ~ 14 days)*

*The observed period for the PR distribution report is tied up with the PR distribution budget used and covers the active period of your PR distribution campaign. The larger the PR distribution budget the longer both the PR distribution campaign and the observed period covered by your PR distribution report.
Report in progress: No
Report is completed: Yes
PR distribution budget: €399
Total reach: 135,873+ (Sep 21, 2018 – Oct 5, 2018 ~ 14 days)
Reach level:
Indicates how optimal your reach is versus the average for the PR distribution budget employed.
Reach level~27%*

* Please note that while this indicator looks into how your reach performed towards the average for the same PR budget, targeting different countries, markets and audiences usually results in significantly different reach level for PR distribution campaigns with the same PR budgets.
TABLE OF CONTENT
1) Where did we publish on, release via and submit to…
2) Who did we target, where and how…
3) Who did we reach out to…
4) Who engaged…
5) Insights…
6) Extend…
WHERE DID WE PUBLISH…
Your press release has been published on, released via, submitted to, and appeared on EuropaWire, the Internet, Web, Search engines, the Blogosphere, News, News aggregators, Social media, etc.
Site URL
EuropaWire: Press release page:

https://news.europawire.eu/new-study-reconfirms-effectiveness-and-safety-of-fotona-dynamis-laser-treatment-for-minimally-invasive-urinary-incontinence-815900/eu-press-release/2018/09/21/

Categories:

https://news.europawire.eu/healthcare/
https://news.europawire.eu/news/
https://news.europawire.eu/pharma-biotech/
https://news.europawire.eu/science/
https://news.europawire.eu/slovenia/
https://news.europawire.eu/technology/

Tags:

https://news.europawire.eu/press-releases-tagged-with/aesthetics/
https://news.europawire.eu/press-releases-tagged-with/bladder/
https://news.europawire.eu/press-releases-tagged-with/chang-gung-memorial-hospital/
https://news.europawire.eu/press-releases-tagged-with/chang-hua-hospital/
https://news.europawire.eu/press-releases-tagged-with/clinical-paper/
https://news.europawire.eu/press-releases-tagged-with/dentistry/
https://news.europawire.eu/press-releases-tagged-with/dermatology/
https://news.europawire.eu/press-releases-tagged-with/dr-adolf-lukanovic/
https://news.europawire.eu/press-releases-tagged-with/dr-mija-blaganje/
https://news.europawire.eu/press-releases-tagged-with/dr-nobuo-okui/
https://news.europawire.eu/press-releases-tagged-with/dr-yi-hao-lin/
https://news.europawire.eu/press-releases-tagged-with/dr-yi-wen-tien/
https://news.europawire.eu/press-releases-tagged-with/dual-tissue-regeneration/
https://news.europawire.eu/press-releases-tagged-with/dynamis-xs/
https://news.europawire.eu/press-releases-tagged-with/eryag-laser-therapy/
https://news.europawire.eu/press-releases-tagged-with/erbium‑doped-yttrium-aluminum-garnet-laser-therapy/
https://news.europawire.eu/press-releases-tagged-with/fotona/
https://news.europawire.eu/press-releases-tagged-with/fotona-d-o-o/
https://news.europawire.eu/press-releases-tagged-with/fotona-smooth-eryag-laser-thermotherapy/
https://news.europawire.eu/press-releases-tagged-with/fotona-smooth-laser-technology/
https://news.europawire.eu/press-releases-tagged-with/fotona-smooth-technology/
https://news.europawire.eu/press-releases-tagged-with/genitourinary-syndrome-of-menopause/
https://news.europawire.eu/press-releases-tagged-with/gynecological-treatment-options/
https://news.europawire.eu/press-releases-tagged-with/gynecologists/
https://news.europawire.eu/press-releases-tagged-with/gynecology/
https://news.europawire.eu/press-releases-tagged-with/iciq-sf/
https://news.europawire.eu/press-releases-tagged-with/incontilase/
https://news.europawire.eu/press-releases-tagged-with/incontilase-eryag/
https://news.europawire.eu/press-releases-tagged-with/incontilase-eryag-laser-therapy/
https://news.europawire.eu/press-releases-tagged-with/international-consultation-on-incontinence-questionnaire-short-form/
https://news.europawire.eu/press-releases-tagged-with/laser-irradiation/
https://news.europawire.eu/press-releases-tagged-with/laser-therapy/
https://news.europawire.eu/press-releases-tagged-with/medical-lasers/
https://news.europawire.eu/press-releases-tagged-with/non-ablative-erbium-yttrium-aluminum-garnet-laser/
https://news.europawire.eu/press-releases-tagged-with/non-invasive-treatment-of-sui/
https://news.europawire.eu/press-releases-tagged-with/one-hour-pad-test/
https://news.europawire.eu/press-releases-tagged-with/overactive-bladder/
https://news.europawire.eu/press-releases-tagged-with/overactive-bladder-symptom-score/
https://news.europawire.eu/press-releases-tagged-with/patient-safety/
https://news.europawire.eu/press-releases-tagged-with/pelvic-organ-prolapse/
https://news.europawire.eu/press-releases-tagged-with/premenopausal-parous-women/
https://news.europawire.eu/press-releases-tagged-with/prolaplase/
https://news.europawire.eu/press-releases-tagged-with/renovalase/
https://news.europawire.eu/press-releases-tagged-with/stress/
https://news.europawire.eu/press-releases-tagged-with/study/
https://news.europawire.eu/press-releases-tagged-with/sui/
https://news.europawire.eu/press-releases-tagged-with/sui-symptoms/
https://news.europawire.eu/press-releases-tagged-with/superficial-heat-shocking-mechanism/
https://news.europawire.eu/press-releases-tagged-with/surgery/
https://news.europawire.eu/press-releases-tagged-with/surgical-sling-procedures/
https://news.europawire.eu/press-releases-tagged-with/tension-free-vaginal-tape/
https://news.europawire.eu/press-releases-tagged-with/tension-free-vaginal-tape-tvt/
https://news.europawire.eu/press-releases-tagged-with/thermotherapy/
https://news.europawire.eu/press-releases-tagged-with/tissue-regeneration/
https://news.europawire.eu/press-releases-tagged-with/tot-procedures/
https://news.europawire.eu/press-releases-tagged-with/transobturator-tape/
https://news.europawire.eu/press-releases-tagged-with/transobturator-tape-tot/
https://news.europawire.eu/press-releases-tagged-with/tvt-procedures/
https://news.europawire.eu/press-releases-tagged-with/urinary-incontinence/
https://news.europawire.eu/press-releases-tagged-with/urodynamic-stress-incontinence/
https://news.europawire.eu/press-releases-tagged-with/vaginal-collagen-hyperthermia/
https://news.europawire.eu/press-releases-tagged-with/vaginal-laxity-vaginal-relaxation-syndrome/
https://news.europawire.eu/press-releases-tagged-with/vaginal-tissues/
https://news.europawire.eu/press-releases-tagged-with/vaginal-wall/
https://news.europawire.eu/press-releases-tagged-with/world-journal-of-urology/

Google: https://www.google.com/search?hl=en&noj=1
Google News: https://www.google.com/search?q=
Bing News: https://www.bing.com/news/search?q=…
Apple News:
(To view this channel open the link on an iPad, iPhone, or iPod touch with iOS 9 or later and Apple News)
https://apple.news/TgIdasElxRICK2SON_8eNPw
Yahoo Search: http://search.yahoo.com/search?…
Bing Search: http://www.bing.com/search?…
Blogosphere: http://www.blogsearchengine.org/search.html?cx=
Twitter: https://twitter.com/europawire

New Study Reconfirms Effectiveness and Safety of Fotona Dynamis Laser Treatment for Minimally-Invasive Urinary Incontinence

https://twitter.com/europawire/status/1044188023527620613
https://t.co/KnEsxYudTk
https://twitter.com/hashtag/urinary_incontinence?src=hash
https://twitter.com/hashtag/laser?src=hash
https://twitter.com/hashtag/medical_lasers?src=hash
https://twitter.com/hashtag/gynecology?src=hash
https://twitter.com/hashtag/gynecologists?src=hash
https://twitter.com/hashtag/bladder?src=hash
https://twitter.com/hashtag/vaginal_tissues?src=hash
https://twitter.com/hashtag/thermotherapy?src=hash
https://twitter.com/bmj_latest
https://twitter.com/jimweb
https://t.co/bI2EADHuCe
https://twitter.com/search?q=place%3A58f54743b1a62911
https://twitter.com/Crille_88
https://twitter.com/HotelMamianiUrb
https://twitter.com/bentoth
https://twitter.com/eprnetwork
https://twitter.com/europawire
https://twitter.com/FotonaLasers
https://twitter.com/fotona_lasers

Study published in World Journal of #Urology confirms Fotona SMOOTH® laser technology is a safe, effective & minimally-invasive solution for stress and mixed #urinary_incontinence

https://twitter.com/europawire/status/1044190999772364800
https://twitter.com/hashtag/Urology?src=hash
https://twitter.com/hashtag/urinary_incontinence?src=hash
https://t.co/KnEsxYLPhU
https://twitter.com/hashtag/medical_lasers?src=hash
https://twitter.com/hashtag/gynecology?src=hash
https://twitter.com/SPIEGEL_Gesund
https://twitter.com/gesundheitd
https://twitter.com/efesalud
https://twitter.com/QSanit
https://t.co/tpUl0gdIdy
https://twitter.com/search?q=place%3A58f54743b1a62911
https://twitter.com/eprnetwork
https://twitter.com/europawire
https://twitter.com/FotonaLasers
https://twitter.com/fotona_lasers
https://twitter.com/wjurol

Study: Comparison between erbium-doped yttrium aluminum garnet laser therapy and sling procedures in the treatment of stress and mixed #urinary_incontinence

https://twitter.com/europawire/status/1044193946472247297
https://twitter.com/hashtag/urinary_incontinence?src=hash
https://t.co/KnEsxYLPhU
https://twitter.com/hashtag/medical_lasers?src=hash
https://twitter.com/hashtag/gynecology?src=hash
https://twitter.com/hashtag/gynecologists?src=hash
https://twitter.com/hashtag/bladder?src=hash
https://twitter.com/hashtag/vaginal_tissues?src=hash
https://twitter.com/DKMA_dk
https://twitter.com/tervefi
https://twitter.com/Vardfokus
https://t.co/0RkInhWC1n
https://twitter.com/search?q=place%3A58f54743b1a62911
https://twitter.com/shin_err
https://twitter.com/Crille_88
https://twitter.com/crazy_jaskolka
https://twitter.com/europawire
https://twitter.com/eprnetwork
https://twitter.com/FotonaLasers
https://twitter.com/fotona_lasers
https://twitter.com/wjurol

Study by Dr. Nobuo Okui compares Fotona’s minimally invasive IncontiLase® Er:YAG #laser therapy with the more conventional TVT and TOT surgical sling procedures

https://twitter.com/europawire/status/1044195619252969472
https://twitter.com/hashtag/laser?src=hash
https://t.co/KnEsxYLPhU
https://twitter.com/hashtag/urinary_incontinence?src=hash
https://twitter.com/hashtag/medical_lasers?src=hash
https://twitter.com/hashtag/gynecology?src=hash
https://twitter.com/TheLancet
https://twitter.com/leQdM
https://twitter.com/medizinaspekte
https://t.co/SXloLB3l1k
https://twitter.com/search?q=place%3A58f54743b1a62911
https://twitter.com/eprnetwork
https://twitter.com/europawire
https://twitter.com/FotonaLasers
https://twitter.com/fotona_lasers
https://twitter.com/wjurol

More than 30 studies on Fotona SMOOTH® #laser_therapy have been published by distinguished #gynecologists over the past few years all with favorable results

https://twitter.com/europawire/status/1044197822302744576
https://twitter.com/hashtag/laser_therapy?src=hash
https://twitter.com/hashtag/gynecologists?src=hash
https://t.co/KnEsxYLPhU
https://twitter.com/hashtag/urinary_incontinence?src=hash
https://twitter.com/hashtag/laser?src=hash
https://twitter.com/hashtag/medical_lasers?src=hash
https://twitter.com/hashtag/gynecology?src=hash
https://twitter.com/hashtag/bladder?src=hash
https://twitter.com/hashtag/vaginal_tissues?src=hash
https://t.co/dps2EtEM5d
https://twitter.com/search?q=place%3A58f54743b1a62911
https://twitter.com/eprnetwork
https://twitter.com/europawire
https://twitter.com/HeelLeClech

Fotona’s Dynamis has been cleared in the EU for SUI (IncontiLase®), #vaginal_laxity – #vaginal_relaxation syndrome (IntimaLase®), #genitourinary_syndrome of #menopause – GSM (RenovaLase®) and pelvic organ prolapse (ProlapLase®)

https://twitter.com/europawire/status/1044205772165586945
https://twitter.com/hashtag/vaginal_laxity?src=hash
https://twitter.com/hashtag/vaginal_relaxation?src=hash
https://twitter.com/hashtag/genitourinary_syndrome?src=hash
https://twitter.com/hashtag/menopause?src=hash
https://t.co/KnEsxYLPhU
https://twitter.com/hashtag/gynecology?src=hash
https://t.co/Sa21VJgEzj
https://twitter.com/search?q=place%3A58f54743b1a62911
https://twitter.com/EddieMeister300
https://twitter.com/Crille_88
https://twitter.com/eprnetwork
https://twitter.com/europawire

Asian Study Confirms Favorable Results of Fotona SMOOTH® Laser Therapy for Urinary Incontinence

https://twitter.com/europawire/status/1044207338729627649
https://t.co/KnEsxYudTk
https://twitter.com/hashtag/urinary_incontinence?src=hash
https://twitter.com/hashtag/laser?src=hash
https://twitter.com/hashtag/medical_lasers?src=hash
https://twitter.com/hashtag/gynecology?src=hash
https://twitter.com/hashtag/gynecologists?src=hash
https://twitter.com/hashtag/bladder?src=hash
https://twitter.com/hashtag/vaginal_tissues?src=hash
https://twitter.com/hashtag/thermotherapy?src=hash
https://twitter.com/IMN_doctors
https://twitter.com/LeFigaro_Sante
https://twitter.com/SZ_Gesundheit
https://t.co/fyCqyt6E4s
https://twitter.com/search?q=place%3A58f54743b1a62911
https://twitter.com/Vickyfairies
https://twitter.com/eprnetwork
https://twitter.com/europawire
https://twitter.com/FotonaLasers
https://twitter.com/fotona_lasers
https://twitter.com/wjurol

Study published in World Journal of Urology confirms Fotona SMOOTH® #laser technology is a safe, effective & minimally-invasive solution for stress and mixed #urinary_incontinence

https://twitter.com/eprnetwork/status/1044224535728459776
https://twitter.com/hashtag/laser?src=hash
https://twitter.com/hashtag/urinary_incontinence?src=hash
https://t.co/Rj9gQ8Gmo5
https://twitter.com/hashtag/medical_lasers?src=hash
https://twitter.com/hashtag/gynecology?src=hash
https://twitter.com/hashtag/gynecologists?src=hash
https://twitter.com/hashtag/bladder?src=hash
https://twitter.com/hashtag/vaginal_tissues?src=hash

Asian Study Confirms Favorable Results of Fotona SMOOTH® Laser Therapy for Urinary Incontinence

https://twitter.com/eprnetwork/status/1044226594485792768
https://t.co/l3JZfmfFdd
https://twitter.com/hashtag/urinary_incontinence?src=hash
https://twitter.com/hashtag/laser?src=hash
https://twitter.com/hashtag/medical_lasers?src=hash
https://twitter.com/hashtag/gynecology?src=hash
https://twitter.com/hashtag/gynecologists?src=hash
https://twitter.com/hashtag/bladder?src=hash
https://twitter.com/hashtag/vaginal_tissues?src=hash
https://twitter.com/hashtag/thermotherapy?src=hash

Facebook:

https://www.facebook.com/EuropaWire

NEW STUDY RECONFIRMS EFFECTIVENESS AND SAFETY OF FOTONA DYNAMIS LASER TREATMENT FOR MINIMALLY-INVASIVE URINARY INCONTINENCE

https://www.facebook.com/EuropaWire/posts/1508325659312887
https://www.facebook.com/hashtag/urinary_incontinence
https://www.facebook.com/hashtag/laser
https://www.facebook.com/hashtag/medical_lasers
https://www.facebook.com/hashtag/gynecology
https://www.facebook.com/hashtag/gynecologists
https://www.facebook.com/hashtag/bladder
https://www.facebook.com/hashtag/vaginal_tissues
https://www.facebook.com/hashtag/thermotherapy
https://www.facebook.com/lasers4dentistry
https://www.facebook.com/EuropaWire/photos/a.450468198431977/1508324249313028

STUDY PUBLISHED IN WORLD JOURNAL OF UROLOGY CONFIRMS FOTONA SMOOTH® LASER TECHNOLOGY IS A SAFE, EFFECTIVE & MINIMALLY-INVASIVE SOLUTION FOR STRESS AND MIXED URINARY INCONTINENCE

https://www.facebook.com/EuropaWire/posts/1508332019312251
https://www.facebook.com/hashtag/urinary_incontinence
https://www.facebook.com/hashtag/laser
https://www.facebook.com/hashtag/medical_lasers
https://www.facebook.com/hashtag/gynecology
https://www.facebook.com/hashtag/gynecologists
https://www.facebook.com/hashtag/bladder
https://www.facebook.com/hashtag/vaginal_tissues
https://www.facebook.com/hashtag/thermotherapy
https://www.facebook.com/lasers4dentistry
https://www.facebook.com/EuropaWire/photos/a.450468198431977/1508331892645597

STUDY: COMPARISON BETWEEN ERBIUM-DOPED YTTRIUM ALUMINUM GARNET LASER THERAPY AND SLING PROCEDURES IN THE TREATMENT OF STRESS AND MIXED URINARY INCONTINENCE

https://www.facebook.com/EuropaWire/posts/1508333325978787
https://www.facebook.com/hashtag/urinary_incontinence
https://www.facebook.com/hashtag/laser
https://www.facebook.com/hashtag/medical_lasers
https://www.facebook.com/hashtag/gynecology
https://www.facebook.com/hashtag/gynecologists
https://www.facebook.com/hashtag/bladder
https://www.facebook.com/hashtag/vaginal_tissues
https://www.facebook.com/hashtag/thermotherapy
https://www.facebook.com/lasers4dentistry
https://www.facebook.com/EuropaWire/photos/a.450468198431977/1508333232645463

STUDY BY DR. NOBUO OKUI COMPARES FOTONA’S MINIMALLY INVASIVE INCONTILASE® ER:YAG LASER THERAPY WITH THE MORE CONVENTIONAL TVT AND TOT SURGICAL SLING PROCEDURES

https://www.facebook.com/EuropaWire/posts/1508334915978628
https://www.facebook.com/hashtag/urinary_incontinence
https://www.facebook.com/hashtag/laser
https://www.facebook.com/hashtag/medical_lasers
https://www.facebook.com/hashtag/gynecology
https://www.facebook.com/hashtag/gynecologists
https://www.facebook.com/hashtag/bladder
https://www.facebook.com/hashtag/vaginal_tissues
https://www.facebook.com/hashtag/thermotherapy
https://www.facebook.com/lasers4dentistry
https://www.facebook.com/EuropaWire/photos/a.450468198431977/1508334765978643

MORE THAN 30 STUDIES ON FOTONA SMOOTH® #LASER_THERAPY HAVE BEEN PUBLISHED BY DISTINGUISHED GYNECOLOGISTS OVER THE PAST FEW YEARS ALL WITH FAVORABLE RESULTS

https://www.facebook.com/EuropaWire/posts/1508335695978550
https://www.facebook.com/hashtag/urinary_incontinence
https://www.facebook.com/hashtag/laser
https://www.facebook.com/hashtag/medical_lasers
https://www.facebook.com/hashtag/gynecology
https://www.facebook.com/hashtag/gynecologists
https://www.facebook.com/hashtag/bladder
https://www.facebook.com/hashtag/vaginal_tissues
https://www.facebook.com/hashtag/thermotherapy
https://www.facebook.com/lasers4dentistry
https://www.facebook.com/EuropaWire/photos/a.450468198431977/1508335642645222

FOTONA’S DYNAMIS HAS BEEN CLEARED IN THE EU FOR SUI (INCONTILASE®), VAGINAL LAXITY – VAGINAL RELAXATION SYNDROME (INTIMALASE®), GENITOURINARY SYNDROME OF MENOPAUSE – GSM (RENOVALASE®) AND PELVIC ORGAN PROLAPSE (PROLAPLASE®)

https://www.facebook.com/EuropaWire/posts/1508336709311782
https://www.facebook.com/hashtag/urinary_incontinence
https://www.facebook.com/hashtag/laser
https://www.facebook.com/hashtag/medical_lasers
https://www.facebook.com/hashtag/gynecology
https://www.facebook.com/hashtag/gynecologists
https://www.facebook.com/hashtag/bladder
https://www.facebook.com/hashtag/vaginal_tissues
https://www.facebook.com/hashtag/thermotherapy
https://www.facebook.com/lasers4dentistry
https://www.facebook.com/EuropaWire/photos/a.450468198431977/1508336662645120

ASIAN STUDY CONFIRMS FAVORABLE RESULTS OF FOTONA SMOOTH® LASER THERAPY FOR URINARY INCONTINENCE

https://www.facebook.com/EuropaWire/posts/1508337635978356
https://www.facebook.com/hashtag/urinary_incontinence
https://www.facebook.com/hashtag/laser
https://www.facebook.com/hashtag/medical_lasers
https://www.facebook.com/hashtag/gynecology
https://www.facebook.com/hashtag/gynecologists
https://www.facebook.com/hashtag/bladder
https://www.facebook.com/hashtag/vaginal_tissues
https://www.facebook.com/hashtag/thermotherapy
https://www.facebook.com/lasers4dentistry
https://www.facebook.com/EuropaWire/photos/a.450468198431977/1508337449311708/

Instagram: N/A
G+ https://plus.google.com/+EuropaWire

https://plus.google.com/b/107823740277361235623/+EuropaWire/posts/Mn8pnKrANZs
https://plus.google.com/s/%23urinary_incontinence/posts
https://plus.google.com/s/%23laser/posts
https://plus.google.com/s/%23medical_lasers/posts
https://plus.google.com/s/%23gynecology/posts
https://plus.google.com/s/%23gynecologists/posts
https://plus.google.com/s/%23bladder/posts
https://plus.google.com/s/%23vaginal_tissues/posts
https://plus.google.com/s/%23thermotherapy/posts

https://plus.google.com/b/107823740277361235623/+EuropaWire/posts/QBfuXjJQMtZ
https://plus.google.com/s/%23urinary_incontinence/posts
https://plus.google.com/s/%23laser/posts
https://plus.google.com/s/%23medical_lasers/posts
https://plus.google.com/s/%23gynecology/posts
https://plus.google.com/s/%23gynecologists/posts
https://plus.google.com/s/%23bladder/posts
https://plus.google.com/s/%23vaginal_tissues/posts
https://plus.google.com/s/%23thermotherapy/posts

https://plus.google.com/b/107823740277361235623/+EuropaWire/posts/fkgck9H2MAS
https://plus.google.com/s/%23urinary_incontinence/posts
https://plus.google.com/s/%23laser/posts
https://plus.google.com/s/%23medical_lasers/posts
https://plus.google.com/s/%23gynecology/posts
https://plus.google.com/s/%23gynecologists/posts
https://plus.google.com/s/%23bladder/posts
https://plus.google.com/s/%23vaginal_tissues/posts
https://plus.google.com/s/%23thermotherapy/posts

https://plus.google.com/b/107823740277361235623/+EuropaWire/posts/hhCdSFENQHo
https://plus.google.com/s/%23urinary_incontinence/posts
https://plus.google.com/s/%23laser/posts
https://plus.google.com/s/%23medical_lasers/posts
https://plus.google.com/s/%23gynecology/posts
https://plus.google.com/s/%23gynecologists/posts
https://plus.google.com/s/%23bladder/posts
https://plus.google.com/s/%23vaginal_tissues/posts
https://plus.google.com/s/%23thermotherapy/posts

https://plus.google.com/b/107823740277361235623/+EuropaWire/posts/GyLkjnScXGw
https://plus.google.com/s/%23urinary_incontinence/posts
https://plus.google.com/s/%23laser/posts
https://plus.google.com/s/%23medical_lasers/posts
https://plus.google.com/s/%23gynecology/posts
https://plus.google.com/s/%23gynecologists/posts
https://plus.google.com/s/%23bladder/posts
https://plus.google.com/s/%23vaginal_tissues/posts
https://plus.google.com/s/%23thermotherapy/posts

https://plus.google.com/b/107823740277361235623/+EuropaWire/posts/EqkDQB63kvi
https://plus.google.com/s/%23urinary_incontinence/posts
https://plus.google.com/s/%23laser/posts
https://plus.google.com/s/%23medical_lasers/posts
https://plus.google.com/s/%23gynecology/posts
https://plus.google.com/s/%23gynecologists/posts
https://plus.google.com/s/%23bladder/posts
https://plus.google.com/s/%23vaginal_tissues/posts
https://plus.google.com/s/%23thermotherapy/posts

https://plus.google.com/b/107823740277361235623/+EuropaWire/posts/bpPXWpnGrgd
https://plus.google.com/s/%23urinary_incontinence/posts
https://plus.google.com/s/%23laser/posts
https://plus.google.com/s/%23medical_lasers/posts
https://plus.google.com/s/%23gynecology/posts
https://plus.google.com/s/%23gynecologists/posts
https://plus.google.com/s/%23bladder/posts
https://plus.google.com/s/%23vaginal_tissues/posts
https://plus.google.com/s/%23thermotherapy/posts

Pinterest: https://www.pinterest.com/europawire

https://www.pinterest.com/europawire/healthcare/
https://www.pinterest.com/europawire/pharma-biotech/
https://www.pinterest.com/europawire/science/
https://www.pinterest.com/europawire/technology/
https://www.pinterest.com/pin/399413060699148894/
https://www.pinterest.com/pin/399413060699148890/
https://www.pinterest.com/pin/399413060699148893/
https://www.pinterest.com/pin/399413060699148901/
https://www.pinterest.com/pin/399413060699148912/
https://www.pinterest.com/pin/399413060699148914/
https://www.pinterest.com/pin/399413060699148918/
https://www.pinterest.com/pin/399413060699148921/

Flipboard: https://flipboard.com/@europawire

https://flipboard.com/@europawire/healthcare-vkgkndpcy
https://flipboard.com/@europawire/pharma-%26-biotech-t3albt3dy
https://flipboard.com/@europawire/science-0tcm80agy
https://flipboard.com/@europawire/technology-nae4rbdey

crunchbase:

https://www.crunchbase.com/organization/fotona
https://www.crunchbase.com/organization/agic-capital

Paper.li: https://paper.li/e-1431004197
EPR HEALTHCARE NEWS:

https://www.eprhealthcarenews.com/2018/09/24/study-published-in-world-journal-of-urology-confirms-fotona-smooth-laser-technology-is-a-safe-effective-minimally-invasive-solution-for-stress-and-mixed-urinary-incontinence/
https://www.eprhealthcarenews.com/category/alternative-medicine/
https://www.eprhealthcarenews.com/category/disorders/
https://www.eprhealthcarenews.com/category/healthcare/
https://www.eprhealthcarenews.com/category/healthcare-products/
https://www.eprhealthcarenews.com/category/healthcare-services/
https://www.eprhealthcarenews.com/category/healthcare-solutions/
https://www.eprhealthcarenews.com/category/non-surgical-procedure/
https://www.eprhealthcarenews.com/category/therapies/
https://www.eprhealthcarenews.com/category/urology/
https://www.eprhealthcarenews.com/tag/aesthetics/
https://www.eprhealthcarenews.com/tag/bladder/
https://www.eprhealthcarenews.com/tag/chang-gung-memorial-hospital/
https://www.eprhealthcarenews.com/tag/chang-hua-hospital/
https://www.eprhealthcarenews.com/tag/clinical-paper/
https://www.eprhealthcarenews.com/tag/dentistry/
https://www.eprhealthcarenews.com/tag/dermatology/
https://www.eprhealthcarenews.com/tag/dr-adolf-lukanovic/
https://www.eprhealthcarenews.com/tag/dr-mija-blaganje/
https://www.eprhealthcarenews.com/tag/dr-nobuo-okui/
https://www.eprhealthcarenews.com/tag/dr-yi-hao-lin/
https://www.eprhealthcarenews.com/tag/dr-yi-wen-tien/
https://www.eprhealthcarenews.com/tag/dual-tissue-regeneration/
https://www.eprhealthcarenews.com/tag/dynamis-xs/
https://www.eprhealthcarenews.com/tag/eryag-laser-therapy/
https://www.eprhealthcarenews.com/tag/erbium‑doped-yttrium-aluminum-garnet-laser-therapy/
https://www.eprhealthcarenews.com/tag/fotona/
https://www.eprhealthcarenews.com/tag/fotona-d-o-o/
https://www.eprhealthcarenews.com/tag/fotona-smooth-eryag-laser-thermotherapy/
https://www.eprhealthcarenews.com/tag/fotona-smooth-laser-technology/
https://www.eprhealthcarenews.com/tag/fotona-smooth-technology/
https://www.eprhealthcarenews.com/tag/genitourinary-syndrome-of-menopause/
https://www.eprhealthcarenews.com/tag/gynecological-treatment-options/
https://www.eprhealthcarenews.com/tag/gynecologists/
https://www.eprhealthcarenews.com/tag/gynecology/
https://www.eprhealthcarenews.com/tag/iciq-sf/
https://www.eprhealthcarenews.com/tag/incontilase/
https://www.eprhealthcarenews.com/tag/incontilase-eryag/
https://www.eprhealthcarenews.com/tag/incontilase-eryag-laser-therapy/
https://www.eprhealthcarenews.com/tag/international-consultation-on-incontinence-questionnaire-short-form/
https://www.eprhealthcarenews.com/tag/laser/
https://www.eprhealthcarenews.com/tag/laser-irradiation/
https://www.eprhealthcarenews.com/tag/laser-therapy/
https://www.eprhealthcarenews.com/tag/medical-lasers/
https://www.eprhealthcarenews.com/tag/non-ablative-erbium-yttrium-aluminum-garnet-laser/
https://www.eprhealthcarenews.com/tag/non-invasive-treatment-of-sui/
https://www.eprhealthcarenews.com/tag/one-hour-pad-test/
https://www.eprhealthcarenews.com/tag/overactive-bladder/
https://www.eprhealthcarenews.com/tag/overactive-bladder-symptom-score/
https://www.eprhealthcarenews.com/tag/patient-safety/
https://www.eprhealthcarenews.com/tag/pelvic-organ-prolapse/
https://www.eprhealthcarenews.com/tag/premenopausal-parous-women/
https://www.eprhealthcarenews.com/tag/prolaplase/
https://www.eprhealthcarenews.com/tag/renovalase/
https://www.eprhealthcarenews.com/tag/stress/
https://www.eprhealthcarenews.com/tag/study/
https://www.eprhealthcarenews.com/tag/sui/
https://www.eprhealthcarenews.com/tag/sui-symptoms/
https://www.eprhealthcarenews.com/tag/superficial-heat-shocking-mechanism/
https://www.eprhealthcarenews.com/tag/surgery/
https://www.eprhealthcarenews.com/tag/surgical-sling-procedures/
https://www.eprhealthcarenews.com/tag/tension-free-vaginal-tape/
https://www.eprhealthcarenews.com/tag/tension-free-vaginal-tape-tvt/
https://www.eprhealthcarenews.com/tag/thermotherapy/
https://www.eprhealthcarenews.com/tag/tissue-regeneration/
https://www.eprhealthcarenews.com/tag/tot-procedures/
https://www.eprhealthcarenews.com/tag/transobturator-tape/
https://www.eprhealthcarenews.com/tag/transobturator-tape-tot/
https://www.eprhealthcarenews.com/tag/tvt-procedures/
https://www.eprhealthcarenews.com/tag/urinary-incontinence/
https://www.eprhealthcarenews.com/tag/urodynamic-stress-incontinence/
https://www.eprhealthcarenews.com/tag/vaginal-collagen-hyperthermia/
https://www.eprhealthcarenews.com/tag/vaginal-laxity-vaginal-relaxation-syndrome/
https://www.eprhealthcarenews.com/tag/vaginal-tissues/
https://www.eprhealthcarenews.com/tag/vaginal-wall/
https://www.eprhealthcarenews.com/tag/world-journal-of-urology-urinary-incontinence/

EPR BIOTECH NEWS:

https://www.eprbiotechnews.com/2018/09/24/asian-study-confirms-favorable-results-of-fotona-smooth-laser-therapy-for-urinary-incontinence/
https://www.eprbiotechnews.com/category/biomedical-engineering/
https://www.eprbiotechnews.com/category/biopharmaceutical/
https://www.eprbiotechnews.com/category/biotech/
https://www.eprbiotechnews.com/category/biotech-products/
https://www.eprbiotechnews.com/category/biotech-services/
https://www.eprbiotechnews.com/category/biotech-solutions/
https://www.eprbiotechnews.com/category/biotechnology/
https://www.eprbiotechnews.com/category/medical-technologies/
https://www.eprbiotechnews.com/tag/aesthetics/
https://www.eprbiotechnews.com/tag/bladder/
https://www.eprbiotechnews.com/tag/chang-gung-memorial-hospital/
https://www.eprbiotechnews.com/tag/chang-hua-hospital/
https://www.eprbiotechnews.com/tag/clinical-paper/
https://www.eprbiotechnews.com/tag/dentistry/
https://www.eprbiotechnews.com/tag/dermatology/
https://www.eprbiotechnews.com/tag/dr-adolf-lukanovic/
https://www.eprbiotechnews.com/tag/dr-mija-blaganje/
https://www.eprbiotechnews.com/tag/dr-nobuo-okui/
https://www.eprbiotechnews.com/tag/dr-yi-hao-lin/
https://www.eprbiotechnews.com/tag/dr-yi-wen-tien/
https://www.eprbiotechnews.com/tag/dual-tissue-regeneration/
https://www.eprbiotechnews.com/tag/dynamis-xs/
https://www.eprbiotechnews.com/tag/eryag-laser-therapy/
https://www.eprbiotechnews.com/tag/erbium‑doped-yttrium-aluminum-garnet-laser-therapy/
https://www.eprbiotechnews.com/tag/fotona/
https://www.eprbiotechnews.com/tag/fotona-d-o-o/
https://www.eprbiotechnews.com/tag/fotona-smooth-eryag-laser-thermotherapy/
https://www.eprbiotechnews.com/tag/fotona-smooth-laser-technology/
https://www.eprbiotechnews.com/tag/fotona-smooth-technology/
https://www.eprbiotechnews.com/tag/genitourinary-syndrome-of-menopause/
https://www.eprbiotechnews.com/tag/gynecological-treatment-options/
https://www.eprbiotechnews.com/tag/gynecologists/
https://www.eprbiotechnews.com/tag/gynecology/
https://www.eprbiotechnews.com/tag/iciq-sf/
https://www.eprbiotechnews.com/tag/incontilase/
https://www.eprbiotechnews.com/tag/incontilase-eryag/
https://www.eprbiotechnews.com/tag/incontilase-eryag-laser-therapy/
https://www.eprbiotechnews.com/tag/international-consultation-on-incontinence-questionnaire-short-form/
https://www.eprbiotechnews.com/tag/laser/
https://www.eprbiotechnews.com/tag/laser-irradiation/
https://www.eprbiotechnews.com/tag/laser-therapy/
https://www.eprbiotechnews.com/tag/medical-lasers/
https://www.eprbiotechnews.com/tag/non-ablative-erbium-yttrium-aluminum-garnet-laser/
https://www.eprbiotechnews.com/tag/non-invasive-treatment-of-sui/
https://www.eprbiotechnews.com/tag/one-hour-pad-test/
https://www.eprbiotechnews.com/tag/overactive-bladder/
https://www.eprbiotechnews.com/tag/overactive-bladder-symptom-score/
https://www.eprbiotechnews.com/tag/patient-safety/
https://www.eprbiotechnews.com/tag/pelvic-organ-prolapse/
https://www.eprbiotechnews.com/tag/premenopausal-parous-women/
https://www.eprbiotechnews.com/tag/prolaplase/
https://www.eprbiotechnews.com/tag/renovalase/
https://www.eprbiotechnews.com/tag/stress/
https://www.eprbiotechnews.com/tag/study/
https://www.eprbiotechnews.com/tag/sui/
https://www.eprbiotechnews.com/tag/sui-symptoms/
https://www.eprbiotechnews.com/tag/superficial-heat-shocking-mechanism/
https://www.eprbiotechnews.com/tag/surgery/
https://www.eprbiotechnews.com/tag/surgical-sling-procedures/
https://www.eprbiotechnews.com/tag/tension-free-vaginal-tape/
https://www.eprbiotechnews.com/tag/tension-free-vaginal-tape-tvt/
https://www.eprbiotechnews.com/tag/thermotherapy/
https://www.eprbiotechnews.com/tag/tissue-regeneration/
https://www.eprbiotechnews.com/tag/tot-procedures/
https://www.eprbiotechnews.com/tag/transobturator-tape/
https://www.eprbiotechnews.com/tag/transobturator-tape-tot/
https://www.eprbiotechnews.com/tag/tvt-procedures/
https://www.eprbiotechnews.com/tag/urinary-incontinence/
https://www.eprbiotechnews.com/tag/urodynamic-stress-incontinence/
https://www.eprbiotechnews.com/tag/vaginal-collagen-hyperthermia/
https://www.eprbiotechnews.com/tag/vaginal-laxity-vaginal-relaxation-syndrome/
https://www.eprbiotechnews.com/tag/vaginal-tissues/
https://www.eprbiotechnews.com/tag/vaginal-wall/
https://www.eprbiotechnews.com/tag/world-journal-of-urology-urinary-incontinence/

WHO DID WE TARGET…
Countries, markets, verticals, audiences, interests, industries, categories, keywords, tags, etc.
Countries: Germany (EU)
France (EU)
United Kingdom (EU)
Italy (EU)
Spain (EU)
Netherlands (EU)
Sweden (EU)
Poland (EU)
Belgium (EU)
Austria (EU)
Denmark (EU)
Finland (EU)
Greece (EU)
Portugal (EU)
Ireland (EU)
Czech Republic (EU)
Romania (EU)
Hungary (EU)
Slovakia (EU)
Croatia (EU)
Luxembourg (EU)
Bulgaria (EU)
Slovenia (EU)
Lithuania (EU)
Latvia (EU)
Cyprus (EU)
Estonia (EU)
Malta (EU)
Russia
Turkey
Switzerland
Norway
Ukraine
Belarus
Serbia
Bosnia and Herzegovina
Albania
FYR of Macedonia
Moldova
Montenegro
Andorra
Iceland
Isle of Man
Jersey
Liechtenstein
Monaco
San Marino
Language: English
Regions, Metros, DMAs, Cities, Towns, etc.: N/A
Industries: Healthcare, Pharma & Biotech, Science, Technology, etc.
Markets / Verticals: medical lasers, gynecology, urinary incontinence, etc.
Audiences: Internet, search engines and social media users living/residing in Germany (EU), France (EU), United Kingdom (EU), Italy (EU), Spain (EU), Netherlands (EU), Sweden (EU), Poland (EU), Belgium (EU), Austria (EU), Denmark (EU), Finland (EU), Greece (EU), Portugal (EU), Ireland (EU), Czech Republic (EU), Romania (EU), Hungary (EU), Slovakia (EU), Croatia (EU), Luxembourg (EU), Bulgaria (EU), Slovenia (EU), Lithuania (EU), Latvia (EU), Cyprus (EU), Estonia (EU), Malta (EU), Russia, Turkey, Switzerland, Norway, Ukraine, Belarus, Serbia, Bosnia and Herzegovina, Albania, FYR of Macedonia, Moldova, Montenegro, Andorra, Iceland, Isle of Man, Jersey, Liechtenstein, Monaco, San Marino using English language and with identified interests like Healthcare, Pharma & Biotech, Science, Technology, urinary incontinence, laser, medical lasers, gynecology, gynecologists, bladder, vaginal tissues, thermotherapy, etc.
Age: 18-
Gender: All
Interests: Healthcare, Pharma & Biotech, Science, Technology, urinary incontinence, laser, medical lasers, gynecology, gynecologists, bladder, vaginal tissues, thermotherapy, etc.
Categories, Keywords, Tags: Healthcare, Pharma & Biotech, Science, Technology, aesthetics, bladder, Chang Gung Memorial Hospital, Chang-Hua Hospital, clinical paper, dentistry, Dermatology, Dr. Adolf Lukanovic, Dr. Mija Blaganje, Dr. Nobuo Okui, Dr. Yi-Hao Lin, Dr. Yi-Wen Tien, dual-tissue regeneration, Dynamis XS, Er:YAG laser therapy, erbium-doped yttrium aluminum garnet laser therapy, Fotona, Fotona d.o.o., Fotona SMOOTH® Er:YAG laser thermotherapy, Fotona SMOOTH® laser technology, Fotona SMOOTH® technology, genitourinary syndrome of menopause, gynecological treatment options, gynecologists, gynecology, ICIQ-SF, IncontiLase®, IncontiLase® Er:YAG, IncontiLase® Er:YAG laser therapy, International Consultation on Incontinence Questionnaire Short Form, laser irradiation, laser therapy, medical lasers, Non-ablative erbium yttrium aluminum garnet laser, non-invasive treatment of SUI, One-hour pad test, overactive bladder, Overactive bladder symptom score, patient safety, pelvic organ prolapse, premenopausal parous women, ProlapLase®, RenovaLase®, stress, study, SUI, SUI symptoms, superficial heat-shocking mechanism, surgery, surgical sling procedures, Tension-free vaginal tape, tension-free vaginal tape – TVT, thermotherapy, tissue regeneration, TOT procedures, Transobturator tape, transobturator tape – TOT, TVT procedures, urinary incontinence, urodynamic stress incontinence, vaginal collagen hyperthermia, vaginal laxity – vaginal relaxation syndrome, vaginal tissues, vaginal wall, World Journal of Urology, etc.
Platforms: Desktop, mobile
WHO DID WE REACH OUT TO…
Total targeted reach, social media reach, followers, subscribers, etc.
Total generic reach: 23,782 people (Sep 21, 2018 – Oct 5, 2018 ~ 14 days)
Total generic video views: 0 people (Sep 21, 2018 – Oct 5, 2018 ~ 14 days)
Total targeted reach: 112,091 people (Sep 21, 2018 – Oct 5, 2018 ~ 14 days)
Total targeted video views: 0 people (Sep 21, 2018 – Oct 5, 2018 ~ 14 days)
Total reach:
(generic + targeted)
135,873 people (Sep 21, 2018 – Oct 5, 2018 ~ 14 days)
Cost per PR total reach: €0.0029
Who did we reach: 112,091+ internet, search engines and social media users living/residing in Germany (EU), France (EU), United Kingdom (EU), Italy (EU), Spain (EU), Netherlands (EU), Sweden (EU), Poland (EU), Belgium (EU), Austria (EU), Denmark (EU), Finland (EU), Greece (EU), Portugal (EU), Ireland (EU), Czech Republic (EU), Romania (EU), Hungary (EU), Slovakia (EU), Croatia (EU), Luxembourg (EU), Bulgaria (EU), Slovenia (EU), Lithuania (EU), Latvia (EU), Cyprus (EU), Estonia (EU), Malta (EU), Russia, Turkey, Switzerland, Norway, Ukraine, Belarus, Serbia, Bosnia and Herzegovina, Albania, FYR of Macedonia, Moldova, Montenegro, Andorra, Iceland, Isle of Man, Jersey, Liechtenstein, Monaco, San Marino using English language and with identified interests like Healthcare, Pharma & Biotech, Science, Technology, urinary incontinence, laser, medical lasers, gynecology, gynecologists, bladder, vaginal tissues, thermotherapy, etc.
Combined number of followers the PR reached out to:
(Twitter, FB, G+, incl. re-tweets, likes, shares, etc.)
16,793+
Cost per follower reach: €0.023
High profile European influencers reached: 200+

(European/EU politicians, policy makers, government leaders, environmentalists, industrialists, bankers, financiers, c-level execs, top-level managers, professionals, consultants, analysts, investors, high networth individuals, etc.)
Cost per influencer reach: €1.995
Related accounts reached out with your PR message:
(This may also include entities, individuals, accounts, etc. associated with your press release)

FOTONA D.O.O.

@FotonaLasers
@fotona_lasers
@FotonaChoosePerfection (FB)
@fotona-d.d. (linkedin)

AGIC CAPITAL

@agic (linkedin)
@agic-capital (crunchbase)

WORLD JOURNAL OF UROLOGY

@wjurol

Relevant entities, media outlets, editorial desks, journalists, bloggers, influencers, social media accounts, etc. reached out with your PR message:

ENGLISH LANGUAGE MARKETS (EUROPE)

BBC Health News
The BMJ
The Lancet
Guardian Healthcare
Univadis UK
PulseToday
GPonline.com
HealthServiceJournal
Irish Medical News
Irish Medical Times
Medical Independent

@bbchealth
@bmj_latest
@bmjdotcom (FB)
@TheLancet
@GdnHealthcare
@univadisUK
@pulsetoday
@PulseToday.co.uk (FB)
@GPonlinenews
@HSJnews
@HSJ.community (FB)
+HsjCoUk
@IMN_doctors
@IMT_latest
@IrishMedicalTimes (FB)
@med_indonews

FRENCH LANGUAGE MARKETS (EUROPE)

Egora.fr
JIM.fr
LeQuotidienduMédecin
Le Figaro Santé
Allodocteurs
APMnews.com
HOSPIMEDIA
AP-HP
Le Généraliste
Univadis France
Informations Médicales (BE)

@Egorafr
@egorafr-130520827015604/
+107231134959774994401/107231134959774994401
@jimweb
@leQdM
@LeFigaro_Sante
@Allodocteurs
@APMinfos
@HOSPIMEDIA
@APHP
@LeGene_hebdo
@univadisFR

GERMAN LANGUAGE MARKETS (EUROPE)

Deutsches Ärzteblatt
Ärzte Zeitung
SPIEGEL ONLINE Gesundheit
FOCUS Gesundheit
SZ Gesundheit
SpringerMedizin.de
Medical Tribune
ots | Gesundheit
MEDIZIN ASPEKTE
deutsche-gesundheits-nachrichten.de
gesundheit.de
PA_Gesundheit
univadis.de
medonline.at (Medizin Medien Austria)
pharmainside.at
MEDIZIN populär (AT)
Medical Tribune (CH)
Schweizerische Ärztezeitung (CH)
Swiss Medical Weekly (CH)
Swiss Medical Forum (CH)
EMH Schweizerischer Ärzteverlag (CH)

@Dt_Aerzteblatt
@aerzteblatt (FB)
+%C3%A4rzteblatt
@aerztezeitung
@SPIEGEL_Gesund
@focusgesundheit
@SZ_Gesundheit
@SpringerMedizin
@MedTrib_medizin
@ots_gesundheit
@medizinaspekte
@gesundheitd
@gesundheit.de (FB)
@gesundheit-de-701 (xing)
@PA_Gesundheit
@univadis_de
@medonline.at (FB)
@medizinmedienaustria (xing)
@medizinpopulaer (FB)
@MedTribCH
+111535850334386053530
@medicaltribune.ch (FB)
@saez.ch (FB)
@SwissMedicalWeekly (FB)
@SwissMedWkly
@emhmedia (FB)

SPANISH LANGUAGE MARKETS (EUROPE)

EFEsalud
El Mundo Salud
diariomedico
Gaceta Médica
EL GLOBAL
Infosalus
SaluDigital.es
ECSalud.com
Acta Sanitaria
Salud y noticias
Salupedia

@efesalud
@EFEsalud (FB)
+Efesaludhealth
@elmundosalud
@diariomedico
@GacetaMedicaCom
@ElGlobalNet
@infosalus_com
@SaluDigital_es
@ECSalud_com
@ActaSanitaria
@noticiasdesalud
@Salupedia

ITALIAN LANGUAGE MARKETS (EUROPE)

Corriere.it Salute
adnkronos.com/Salute
Sole 24 Ore Sanità
Quotidiano Sanità
24salute
MSD Salute
Doctor33
MedicalExcellence.TV
med observer
Saluteuropa
Medicina Moderna
La Nostra Salute

@Corriere_Salute
@adnk_salute
@24OreSanita
@QSanit
@24salute
@msdsalute
@DoctorNews33
@MedexTV
@medlookout
@Saluteuropa
@MedicinaModerna
@LaNostraSalute

NORDIC LANGUAGES MARKETS (EUROPE)

DK

Dagens Medicin
Nicolai Döllner (Chefredaktør for Dagens Medicin)
Lægeforeningen
Ugeskrift for Læger
UgeskriftetVidenskab
DanishMedicinesAgcy
Medicinsk Tidsskrift
min.medicin.dk
pro.medicin.dk
Dagens Pharma
MedWatch

FI

Terve.fi
Duodecim (Finnish Medical Society)
PotilaanLääkärilehti
Suomen Lääkäriliitto
Lääkärilehti
Mediuutiset
Tehy-lehti

SE

Läkartidningen
Sjukhusläkaren
Läkarförbundet
Dagens Medicin
Vårdfokus
Sjukhusläkarna
DOKTORN.com

NO

Dagens Medisin
Tidsskriftet
Journalen
Sykepleien

DK

@DagensMedicinDK
@NicolaiDollner
@laegeforeningen
@Ugeskriftet
@UgeskriftetVid
@DKMA_dk
@medicinsktidsskrift (FB)
@Minmedicindk (FB)
@Promedicindk (FB)
@DagensPharma
@MedWatchDK

FI

@tervefi
@DuodecimFi
@Potlaakarilehti
@Laakariliitto
@Laakarilehti
@mediuutiset
@Tehylehti

SE

@lakartidn
@Sjukhuslakaren
@sjukhuslakaren (FB)
@lakarforbundet
@dagensmedicin
@Vardfokus
@sjukhuslakarna
@doktornpunktcom

NO

@DagensMedisin
@Tidsskriftet
@Journalen
@Sykepleien1

CENTRAL, EASTERN & SOUTHERN EUROPEAN LANGUAGES MARKETS

PL

rynekzdrowia.pl
Wojciech Kuta (Redaktor Rynek Zdrowia)
Portale Medyczne
medexpress.pl
Menedżer Zdrowia
WprostZdrowie
ZdrowieGazeta.pl

CZ

Zdravotnické noviny
Naše zdravotnictví
ozdravotnictví.cz
uLékaře.cz
prolekare.cz

HU

Orvosi Hírek
InforMed Orvosi portál
Weborvos – online egészségügyi magazin
Napi doktor
HáziPatika.com

RO

romedic.ro
Viaţa Medicală
Dr Oana Cuzino (doc.ro)
Ce se intampla, Doctore?

BG

medicalnews.bg
сп. Мединфо
Clinica.bg
Zdrave.net
PulsBG
Pharmacy Bg

GR

onmed.gr
iatronet.gr
ΙΑΤΡΙΚΟΣ ΤΥΠΟΣ
farmakopoioi
pharmacorner.gr
Vita.gr
Ygeia-News.com

HR

Hrvatsko farmaceutsko društvo
PLIVAzdravlje
Zdravo budi

PL

@rynekzdrowia
@rynekzdrowia (FB)
@wojciech_kuta
@PortaleMedyczne
@medexpresspl
@MenedzerZdrowia
@WprostZdrowie
@zdrowiewprost (FB)
+106393758655828062142/posts
@zdrowie.gazetapl (FB)

CZ

@zdravky (FB)
@Nasezdrav
@nasezdravotnictvi (FB)
@ozdravotnictvi
@uLekare

HU

@orvosihirek (FB)
@informed.hu (FB)
@weborvos (FB)
@napidoktor (FB)
@HaziPatika (FB)

RO

@romedic.ro (FB)
@Viata.Medicala (FB)
@DrOanaCuzino (FB)
@_CSID_
@CSIDOficial (FB)

BG

@medicalnews.bg (FB)
@medinfo.bg (FB)
@clinicabg
@clinica.bg (FB)
+103359434290832577642
@ Zdravenet-102162099889218 (FB)
@PulsBG
@puls.bg (FB)
@Pharmacy-Bg-77809296438 (FB)

GR

@onmedgr
@onmed.gr (FB)
+108620107787695417848
@iatronet (FB)
@iatronet
@IatrikosTypos
@farmakopoioi
@pharmacorner
@vitagr1 (FB)
@YgeiaNews

HR

@farmaceutHFD (FB)
@PLIVAzdravlje (FB)
+107371652060511488921
@zdravobudi.hr (FB)



(When targeting is too broad — too many countries, audiences, industries and markets are sought after — while the PR budget allocated does not provide the necessary reach and duration of the PR distribution campaign, it becomes nearly impossible to identify the relevant entities to reach out to with your PR message.)

WHO ENGAGED…
PR title views and displays, PR reads, engagements, social media insights, analytics and metrics, mentions, interactions, likes, tweets/retweets, shares, comments, replies, etc.
PR title views/displays:
(generic + targeted)
135,873+ people
PR video views:
(generic + targeted)
0 people
Cost per PR title view: €0.0029
Cost per PR video view: €0.00
PR total reads: 3,790* precisely targeted people read*** your press release
(Sep 21, 2018 – Oct 5, 2018 ~ 14 days**)

* The total PR reads number above is not final. It only covers the observed period for the PR distribution report, which is the active period of your PR campaign, which on itself depends on the PR distribution budget employed. The total number of people who will read your press release is highly likely to increase over time as your press release matures online and becomes more visible in the search engines, the blogoshpere and the social media space as well. Frequent updates are however only done during the active period of your PR distribution campaign, which is correlated to the PR distribution budget you’ve chosen and may be anything between one week and 30+ days with larger PR distribution budgets used. Further updates on this PR distribution report beyond the PR campaign period may be done on an irregular basis. If such an update is made on your PR distribution report in the future, EuropaWire will send a notification on the email address associated with this account.

** The observed period for the PR distribution report is tied up with the PR distribution budget used and covers the active period of your PR distribution campaign. The larger the PR distribution budget the longer both the PR distribution campaign and the observed period covered by your PR distribution report.

*** Read definition: For the sake of the metrics the read is considered and only counted as such, if the following conditions are met: 1) The press release page has fully been loaded in the browser and the time spent on the page by the visitor is at least 30 seconds; 2) An IP address is only counted once per 24 hours regardless how many times the same IP returned on the press release content; 3) Press release content viewed on social media sites do count as reads if and only when there are clear engagements (e.g. likes/loves, shares, tweets, re-tweets, etc.) reported by the respective social media accounts’ metrics and we have an access to and control over those accounts the event/engagement happened on in order to confirm/vitrify; 4) PR title viewed as well as PR title + excerpts viewed, either on the site or on social media accounts and third party sites and places, do NOT count as reads for the purpose of this report; 5) In general and by default press release reads are always more than what we can duly report in our press release distribution reports as we CANNOT gather data for press release content views, reads, shares, mentions, references, etc., on third party sites, social media accounts, private emails and communications (messengers, etc.) that are beyond our control and we have no access to their analytics and metrics; 6) Press release title and content, either partly or in its entirety, displayed, or served to viewers in the form of impressions, either on site, on third party sites or on social media, are not included in the metrics of this report as qualified reads, as we cannot tell how many of those displays/impressions can really be considered as qualified reads (e.g. no reliable data on how long the viewer engaged with the PR content AND/OR not sure whether the viewer was actually interested in what was displayed to her/him). However, it is realistic to assume certain amount of those displays and impressions can also be considered as qualified reads for the metrics of this report. We however, cannot report how many of them qualify as real reads of the press release, hence, do not have them included in this report; 7) And in general all views and reads, having occurred on sites, places and accounts we were not made aware of upon the closure of this PR distribution report are NOT counted and included in as reads; 8) Bots, in any form, type and shape, are by default excluded from the metrics of this report, whenever detected, known and possible.
Cost per PR read: €0.10
PR title views / PR reads ratio: 2.78%
Who read*** your press release: 3,790 precisely targeted individuals living/residing in Germany (EU), France (EU), United Kingdom (EU), Italy (EU), Spain (EU), Netherlands (EU), Sweden (EU), Poland (EU), Belgium (EU), Austria (EU), Denmark (EU), Finland (EU), Greece (EU), Portugal (EU), Ireland (EU), Czech Republic (EU), Romania (EU), Hungary (EU), Slovakia (EU), Croatia (EU), Luxembourg (EU), Bulgaria (EU), Slovenia (EU), Lithuania (EU), Latvia (EU), Cyprus (EU), Estonia (EU), Malta (EU), Russia, Turkey, Switzerland, Norway, Ukraine, Belarus, Serbia, Bosnia and Herzegovina, Albania, FYR of Macedonia, Moldova, Montenegro, Andorra, Iceland, Isle of Man, Jersey, Liechtenstein, Monaco, San Marino that speak/read English and are interested in and like Healthcare, Pharma & Biotech, Science, Technology, urinary incontinence, laser, medical lasers, gynecology, gynecologists, bladder, vaginal tissues, thermotherapy, etc.



*** Read definition: For the sake of the metrics the read is considered and only counted as such, if the following conditions are met: 1) The press release page has fully been loaded in the browser and the time spent on the page by the visitor is at least 30 seconds; 2) An IP address is only counted once per 24 hours regardless how many times the same IP returned on the press release content; 3) Press release content viewed on social media sites do count as reads if and only when there are clear engagements (e.g. likes/loves, shares, tweets, re-tweets, etc.) reported by the respective social media accounts’ metrics and we have an access to and control over those accounts the event/engagement happened on in order to confirm/vitrify; 4) PR title viewed as well as PR title + excerpts viewed, either on the site or on social media accounts and third party sites and places, do NOT count as reads for the purpose of this report; 5) In general and by default press release reads are always more than what we can duly report in our press release distribution reports as we CANNOT gather data for press release content views, reads, shares, mentions, references, etc., on third party sites, social media accounts, private emails and communications (messengers, etc.) that are beyond our control and we have no access to their analytics and metrics; 6) Press release title and content, either partly or in its entirety, displayed, or served to viewers in the form of impressions, either on site, on third party sites or on social media, are not included in the metrics of this report as qualified reads, as we cannot tell how many of those displays/impressions can really be considered as qualified reads (e.g. no reliable data on how long the viewer engaged with the PR content AND/OR not sure whether the viewer was actually interested in what was displayed to her/him). However, it is realistic to assume certain amount of those displays and impressions can also be considered as qualified reads for the metrics of this report. We however, cannot report how many of them qualify as real reads of the press release, hence, do not have them included in this report; 7) And in general all views and reads, having occurred on sites, places and accounts we were not made aware of upon the closure of this PR distribution report are NOT counted and included in as reads; 8) Bots, in any form, type and shape, are by default excluded from the metrics of this report, whenever detected, known and possible.

PR shares: 7
PR likes: 9
PR G+: 7
PR LinkedIn: 0
PR tweets/re-tweets/likes: 48
PR Pinterest: 8
PR Flipboard: 5
PR reactions / comments:
EuropaWire, Search engines, news, Blogosphere, social media, etc.
2

* Please note that PR reactions and comments may happen way beyond the initial active PR distribution campaign period, which is covered by the current PR distribution report and such PR reactions and comments, if any, may be included in future updates on this PR distribution report.
PR mentions:
Third party mentions online as a result of your press release on EuropaWire.
2

* Please note that PR mentions may happen way beyond the initial active PR distribution campaign period, which is covered by the current PR distribution report and such PR mentions, if any, may be included in future updates on this PR distribution report.
INSIGHTS…
PR insights, analyses, rates, averages, conclusions, etc.
Budget vs. target:
Reads vs. target:
Engagement vs. target:
Reach vs. budget:
Reads vs. budget:
Engagement vs. budget:
Reads vs. reach:
Engagement vs. reads:
Engagement vs. reach:
Language vs. target:
Reads vs. language:
Engagement vs. language:
Title vs. audience:
Title vs. target:
Reads vs. title:
EXTEND…
Extend PR distribution campaing to increase reach and engagement, etc.
Extend PR campaign & reach: Based on the PR distribution budget you choose from below, we’ll extend your existing PR distribution campaign for the same press release by using the same settings, preferences, targeting options, etc. The larger the PR distribution budget the longer both the PR distribution campaign and the observed period covered by your PR distribution report.



-END-
GENERAL NOTES:

Should you have any questions about this report, please contact us at info@europawire.eu.Many of the figures, numbers and values included in the PR distribution report above are not final. The current PR distribution report only covers the active period of your PR distribution campaign, which on itself depends on the PR distribution budget employed. Many of the numbers above are highly likely to increase and change over time as your press release matures online and becomes more visible in the search engines, the blogoshpere and the social media space as well. Frequent updates are however only done during the active period of your PR distribution campaign, which is correlated to the PR distribution budget you’ve chosen and may be anything between one week and 30+ days with larger PR distribution budgets used. Further updates on this PR distribution report beyond the PR campaign period may be done on an irregular basis. If such an update is made on your PR distribution report in the future, EuropaWire will send a notification on the email address associated with this account.

Please note that while this PR distribution report is not behind secure page, it is not publicly accessible and unless you give the URL (the web address) away for other people to see it, there is no other way for somebody else to find it out on the Web. No sensitive, private or financial information, if ever made available to us, will ever be published in this report section.

The information in this PR distribution report was factually accurate on the date of its last update (date shown above). This PR distribution report remains on EuropaWire website for historical purposes only. EuropaWire assumes no duty to update the information to reflect subsequent developments beyond the period of the active PR distribution campaign. Readers should not rely upon the information in this PR distribution report as current or accurate after date it was last updated on.

To have an easy and quick access to this report page for further references, please consider bookmarking it.

Thank you for releasing via EuropaWire.

Editorial Staff
EuropaWire